CLINICAL_TRIALS
trial_result
· 2019-09-17
Clinical Trial Update: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed [Phase 3]
Summary
Phase 3 trial update for NGR015 in second-line malignant pleural mesothelioma; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AGC Biologics S.p.A. | Conditions: Malignant Pleural Mesothelioma | Phase 3 | Status: COMPLETED | Results posted: 2019-09-17